» Articles » PMID: 19563606

A Critical Analysis of Current in Vitro and in Vivo Angiogenesis Assays

Overview
Publisher Wiley
Specialty Pathology
Date 2009 Jul 1
PMID 19563606
Citations 195
Authors
Affiliations
Soon will be listed here.
Abstract

The study of angiogenesis has grown exponentially over the past 40 years with the recognition that angiogenesis is essential for numerous pathologies and, more recently, with the advent of successful drugs to inhibit angiogenesis in tumours. The main problem with angiogenesis research remains the choice of appropriate assays to evaluate the efficacy of potential new drugs and to identify potential targets within the angiogenic process. This selection is made more complex by the recognition that heterogeneity occurs, not only within the endothelial cells themselves, but also within the specific microenvironment to be studied. Thus, it is essential to choose the assay conditions and cell types that most closely resemble the angiogenic disease being studied. This is especially important when aiming to translate data from in vitro to in vivo and from preclinical to the clinic. Here we critically review and highlight recent advances in the principle assays in common use including those for endothelial cell proliferation, migration, differentiation and co-culture with fibroblasts and mural cells in vitro, vessel outgrowth from organ cultures and in vivo assays such as chick chorioallantoic membrane (CAM), zebrafish, sponge implantation, corneal, dorsal air sac, chamber and tumour angiogenesis models. Finally, we briefly discuss the direction likely to be taken in future studies, which include the use of increasingly sophisticated imaging analysis systems for data acquisition.

Citing Articles

Type IV collagen derived non-collagenous domain α6 (IV) NC1 and its derivative fragments inhibit endothelial cell proliferation and attenuates chorioallantoic membrane angiogenesis.

Setti A, Pasha A, Makani V, Bhadra M, Pawar S Cytotechnology. 2025; 77(2):47.

PMID: 39867830 PMC: 11759748. DOI: 10.1007/s10616-025-00709-7.


N-Oxalylglycine-Conjugated Hyaluronic Acid as a Macromolecular Prodrug for Therapeutic Angiogenesis.

DeMaria A, Lee J, Webb K Gels. 2025; 11(1).

PMID: 39851998 PMC: 11765021. DOI: 10.3390/gels11010027.


Rethinking Biomedical Titanium Alloy Design: A Review of Challenges from Biological and Manufacturing Perspectives.

Rabbitt D, Villapun V, Carter L, Man K, Lowther M, OKelly P Adv Healthc Mater. 2024; 14(4):e2403129.

PMID: 39711273 PMC: 11804846. DOI: 10.1002/adhm.202403129.


Bioengineering vascularization.

Landau S, Okhovatian S, Zhao Y, Liu C, Shakeri A, Wang Y Development. 2024; 151(23).

PMID: 39611864 PMC: 11698057. DOI: 10.1242/dev.204455.


Prospecting Pharmacologically Active Biocompounds from the Amazon Rainforest: In Vitro Approaches, Mechanisms of Action Based on Chemical Structure, and Perspectives on Human Therapeutic Use.

de Almada-Vilhena A, Dos Santos O, Machado M, Nagamachi C, Pieczarka J Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598361 PMC: 11597570. DOI: 10.3390/ph17111449.


References
1.
Yang M, Baranov E, Wang J, Jiang P, Wang X, Sun F . Direct external imaging of nascent cancer, tumor progression, angiogenesis, and metastasis on internal organs in the fluorescent orthotopic model. Proc Natl Acad Sci U S A. 2002; 99(6):3824-9. PMC: 122608. DOI: 10.1073/pnas.052029099. View

2.
Vollmar B, Scheuer C, Strik M, Bruch H, Menger M . Acceleration of cutaneous wound healing by transient p53 inhibition. Lab Invest. 2002; 82(8):1063-71. DOI: 10.1097/01.lab.0000024363.37866.45. View

3.
Solowiej A, Biswas P, Graesser D, Madri J . Lack of platelet endothelial cell adhesion molecule-1 attenuates foreign body inflammation because of decreased angiogenesis. Am J Pathol. 2003; 162(3):953-62. PMC: 1868115. DOI: 10.1016/S0002-9440(10)63890-4. View

4.
Plunkett M, Hailey J . An in vivo quantitative angiogenesis model using tumor cells entrapped in alginate. Lab Invest. 1990; 62(4):510-7. View

5.
Segura I, Serrano A, de Buitrago G, Gonzalez M, Abad J, Claveria C . Inhibition of programmed cell death impairs in vitro vascular-like structure formation and reduces in vivo angiogenesis. FASEB J. 2002; 16(8):833-41. DOI: 10.1096/fj.01-0819com. View